top of page
shutterstock_290587343.jpg

In less than 5 minutes, learn all about kidney diseases and treatment options

Sparsentan for IgA Nephropathy
 

Worldwide, IgA nephropathy (IgAN) is a leading cause of chronic kidney disease and end-stage kidney disease. Luckily, new treatment options are becoming available. You can learn more about sparsentan (Filspari) here: 

Inaxaplin for APOL1-mediated Kidney Disease

APOL1 genetic variants are linked to an increased risk of kidney disease in people of African descent. Exciting new therapies targeting APOL1-associated kidney disease are on the horizon. Learn more about Inaxaplin here:

bottom of page